

Please type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

FEB 02 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/619,268
Filing Date	July 14, 2003
First Named Inventor	Charles Q. Meng
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	04676.105081 ATH 123US

3389630_1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
P	AA	4,522,811		Eppstein <i>et al.</i>	06-11-1995	
	AB	4,954,514		Kita <i>et al.</i>	09-04-1990	
	AC	5,155,250		Parker <i>et al.</i>	10-13-1992	
	AD	5,262,439		Parthasarathy	11-16-1993	
	AE	5,608,095		Parker <i>et al.</i>	03-04-1997	
	AF	6,121,319		Somers	09-19-2000	
	AG	6,147,250		Somers	11-14-2000	
	AH	2001/0029660	A1	Johnson	10-18-2001	
	AI	2001/0032014	A1	Yang <i>et al.</i>	10-18-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Office ³	Number	Kind Code ² (if known)				
P	AJ	EP	0,348,203 ✓	A1	Shionogi & Co.	12-27-1989		
	AK	EP	0,405,788 ✓	A2	Shionogi & Co.	01-02-1991		
	AL	FR	2130975 ✓		Aries	11-10-1972		
	AM	FR	2133024 ✓		Aries	11-24-1972		
	AN	FR	2134810 ✓		Aries	12-08-1972		
	AO	FR	2140769 ✓		Aries	01-19-1973		
	AP	FR	2140771 ✓		Aries	01-19-1973		
	AQ	FR	2168137 ✓		Dynachim	08-31-1973		Y
	AR	WO	95/15760 ✓		Merrell Dow Pharmaceuticals	06-15-1995		
	AS	WO	01/70757 ✓	A2	Atherogenics	09-27-2001		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known			
		Application Number	10/619,268		
		Filing Date	July 14, 2003		
		First Named Inventor	Charles Q. Meng		
		Group Art Unit	Unassigned		
Sheet	2	of	2	Attorney Docket Number	04676.105081 ATH 123

3389630_1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	BA	BROWN, L., <i>et al.</i> , "Transdermal Delivery of Drugs," <i>Annual Review of Medicine</i> , 39:221-229 (1988).	
	BB	KAPLAN, N.M., "Chapter 26: Systemic hypertension: mechanisms and diagnosis," in <i>Heart Disease</i> , 5 th ed., Braunwald, E., Ed., W.B. Saunders & Co., Philadelphia, 1997, pp. 807-823.	
	BC	MENG, C.Q., <i>et al.</i> , "Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis," <i>Bioorganic & Med. Chem. Ltrs.</i> , 12(18):2545-2548 (2002).	
	BD	SUNDELL, <i>et al.</i> , "AGIX-4207: A novel antioxidant and anti-inflammatory compound inhibits progression of collagen II arthritis in the rat," <i>FASEB Journal</i> , 16(4):A182 (April 20-24, 2002), Annual Meeting of the Professional Research Scientists on Experimental Biology, ISSN 0892-6638.	

3389630_1

Examiner Signature		Date Considered	9/24/04
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.